- Home
- SOCA vs IRWD Comparison
SOCA vs IRWD Comparison
Compare SOCA & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOCA
- IRWD
- Stock Information
- Founded
- SOCA 2025
- IRWD 1998
- Country
- SOCA United States
- IRWD United States
- Employees
- SOCA N/A
- IRWD N/A
- Industry
- SOCA
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- SOCA
- IRWD Health Care
- Exchange
- SOCA Nasdaq
- IRWD Nasdaq
- Market Cap
- SOCA 235.0M
- IRWD 251.8M
- IPO Year
- SOCA 2025
- IRWD 2010
- Fundamental
- Price
- SOCA $10.08
- IRWD $1.59
- Analyst Decision
- SOCA
- IRWD Buy
- Analyst Count
- SOCA 0
- IRWD 5
- Target Price
- SOCA N/A
- IRWD $4.94
- AVG Volume (30 Days)
- SOCA 46.0K
- IRWD 1.2M
- Earning Date
- SOCA 01-01-0001
- IRWD 11-04-2025
- Dividend Yield
- SOCA N/A
- IRWD N/A
- EPS Growth
- SOCA N/A
- IRWD N/A
- EPS
- SOCA N/A
- IRWD N/A
- Revenue
- SOCA N/A
- IRWD $308,519,000.00
- Revenue This Year
- SOCA N/A
- IRWD N/A
- Revenue Next Year
- SOCA N/A
- IRWD N/A
- P/E Ratio
- SOCA N/A
- IRWD N/A
- Revenue Growth
- SOCA N/A
- IRWD N/A
- 52 Week Low
- SOCA $9.94
- IRWD $0.53
- 52 Week High
- SOCA $10.13
- IRWD $5.13
- Technical
- Relative Strength Index (RSI)
- SOCA N/A
- IRWD 56.67
- Support Level
- SOCA N/A
- IRWD $1.43
- Resistance Level
- SOCA N/A
- IRWD $1.77
- Average True Range (ATR)
- SOCA 0.00
- IRWD 0.13
- MACD
- SOCA 0.00
- IRWD -0.00
- Stochastic Oscillator
- SOCA 0.00
- IRWD 38.53
About SOCA Solarius Capital Acquisition Corp. Class A Ordinary Share
Solarius Capital Acquisition Corp is a blank check company.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.